Reversal of neuromuscular block: what are the costs?

Karsten Bartels, Ana Fernandez-Bustamante, Marcos F. Vidal Melo

Research output: Contribution to journalEditorialpeer-review

1 Scopus citations


Patients requiring neuromuscular block for anaesthesia have a higher risk of adverse postoperative outcomes. The choice of reversal drug and its corresponding dose is critical for improving clinical outcomes. Although drug costs are higher for sugammadex relative to neostigmine, additional factors need to be considered when choosing one drug over the other. New data from a recent study in the British Journal of Anaesthesia indicate cost advantages for sugammadex in low-risk and ambulatory patients, but for neostigmine in high-risk patients. These findings highlight the need to take local and temporal factors into consideration in addition to clinical effectiveness when performing cost analyses for administrative decision-making.

Original languageEnglish (US)
Pages (from-to)202-204
Number of pages3
JournalBritish Journal of Anaesthesia
Issue number2
StatePublished - Aug 2023


  • health economics
  • neostigmine
  • neuromuscular blocking agent
  • outcomes
  • postoperative pulmonary complications
  • sugammadex

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Reversal of neuromuscular block: what are the costs?'. Together they form a unique fingerprint.

Cite this